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Non-steroidal anti-inflammatory drugs 
and cardiovascular risk – a rheumatolo-
gist’s reply
To the Editor: The cyclo-oxygenase-2 (COX-2) inhibitors and 
other non-steroidal anti-inflammatory drugs (NSAIDs) have 
been the subject of scrutiny generated mainly by evidence 
suggesting that rofecoxib is associated with increased 
cardiovascular risk. Chin and Commerford1 have summarised 
some of the large volume of data; however, a critical review of 
published work yields interesting insights.
A meta-analysis2 of the cardiovascular risk associated with 
the use of rofecoxib yielded a risk ratio (RR) of 2.24 at 1 year, 
with a confidence interval (CI) of 1.24 - 4.02; a fairly wide 
range but the lower limit above 1. This can be regarded as 
convincing for a relative RR. In the Juni et al. study2 of 14 
studies involving 21 432 patients, there were 64 events; this 
represents 0.0029 events per patient year – not an impressive 
number. The RR for rofecoxib is not demonstrated in many 
other trials assessing cardiovascular risk with celecoxib and 
non-selective NSAIDs that generated risk ratios of less than 2.0 
with CI intervals having lower limits of less than 1.0 in most 
cases.3,4 Publication bias can account for a bias of 1.5, while 
heterogenicity can also influence the risk ratio. Most studies 
corrected for heterogenicity, but current correction techniques 
are not adequate.5
Difficulties in the interpretation of low RRs have been 
acknowledged,3,4 and McGettigan and Henry3 state: ‘Typically, 
there is reluctance in pharmaco-epidemiological studies 
to accept as causal RR estimates much below 2’. A further 
complicatory factor may be found in the dose of NSAIDs in the 
randomised controlled trials, where the doses were typically at 
the upper end of the conventional dosages.6,7
A large cohort study examined 74 838 users of various 
selective and non-selective NSAIDS and found a modest RR 
of 1.14 for rofecoxib, but could not demonstrate an increased 
cardiovascular risk for any of the others.8 Brophy9 accepts that 
a cardiovascular risk is associated with the use of rofecoxib. 
He concludes that studies on celecoxib and other NSAIDs 
have suggested that any risk with coxibs is likely to be small 
and comparable to traditional NSAIDs. Combined with 
the conclusions that celecoxib was not associated with an 
elevated risk of vascular occlusion,3 one can readily conclude 
that these drugs are not associated with an increased risk of 
cardiovascular disease. Gislason et al.10 found that the numbers 
treated to cause an additional death was alarmingly low for 
the preparations examined; however, we are not informed as 
to the causes of death, and a causal effect is assumed. They 
also assumed that the patients consumed the preparations 
purchased. Interestingly, an odds ratio for low-dose ibuprofen 
and diclofenac of 0.57 and 0.86 respectively was documented. 
Can we assume that low doses of these preparations had a 
(mildly) protective effect?
The Nurses Health Study11 found that the highest mortality 
occurred among the older cohort, where risk factors were 
greatest for musculoskeletal pathology and cardiovascular 
risks. The RR for NSAIDs among non-smokers was 1.11, 
compared with 1.82 among smokers. The latter figure could 
explain the modestly raised overall RR. In this study, the RR 
for paracetamol was 1.30, which in pharmaco-epidemiological 
terms carries little significance.3 Cynically, one could comment 
that one can find evidence for almost any point of view except 
for the consistent finding that rofecoxib carries a small increase 
in cardiovascular risk. The argument that there are sound 
physiological reasons for assuming that non-steroidals could be 
associated with cardiovascular events is important. However, 
perhaps we should remember the oestrogen saga.
Another aspect is the importance of these drugs in pain 
relief. NSAIDs have been demonstrated to be more effective 
than analgesics for pain relief in osteoarthritis12 and are critical 
in the treatment of inflammatory back pain.13 I agree that over-
the-counter sale of these drugs should be discouraged, but a 
backlash against them could result in patients being denied 
pain relief. 
David Sackett stated: ‘Without clinical expertise, practice 
risks becoming tyrannised by evidence, for even excellent 
external evidence may be inapplicable to or inappropriate for 
an individual patient’.14 Chin and Commerford have done us 
a service by raising this issue, but I would argue that there is 
sufficient evidence to choose what one wants to believe. This 
discussion has just begun.
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